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THE fluorinated pyrimidines in the form of 5-fluorouracil were introduced to
clinical chemotherapy in 1958 by Curreri, Ansfield, McIver, Waisman and Heidel-
berger. While initial reports might have been highly enthusiastic, larger studies
showed an objective regression rate in the region of 20%, though it was felt that
this regression rate was achieved only at the expense ofhigh toxicity, and a drug
mortality of the order of 5% (Curreri et al., 1958; Moertel and Reitemeier, 1962;
Sullivan and Miller, 1965). The one encouraging feature of this group of drugs
was that responses were obtained in gastrointestinal malignancy as frequently as
in other primaries (Brennan and Vaitkevicos, 1960; Kennedy and Theologides,
1961). Up to that little benefit had been achieved in gastrointestinal adeno-
carcinoma with the alkylating agents, antibiotics and antimetabolites available.
Moertel and Reitemeier's observation (1962) that " 5-fluorouracil must be consid-
ered a significant milestone in chemotherapy " appears quite valid. Almost all
clinical reports on this drug have come from the United States, except for a few
from New Zealand (Watson, 1964), Australia (McCaffrey, 1964) and Italy (Fioren-
tino and Conte, 1963). Most communications were approached from an experi-
mental investigational point of view, rather than from a strictly therapeutic one.
It appears relevant to enquire therefore, why, if a drug is used to such an extent
and available commercially on one side ofthe Atlantic, is it not so accepted on the
other side?
The rationale for the use of the fluorinated pyrimidines is based on observa-
tions that uracil is incorporated in high concentration into the nucleic acids of
rat hepatoma induced chemically, as well as into the intestinal mucosa (Heidel-
berger, Leibman, Harbers and Bhargave, 1957). Substitution of fluorine in the
5 position ofuracil produces a compound, 5-fluorouracil which inhibits thymidilate
synthethase, thus preventing conversion ofdeoxyuridylic acid to thymidylic acid,
one of the bases of DNA. This site of action resembles closely one of the sites
of action of methothrexate. There is also interference with incorporation of
uracil into RNA (Heidelberger, Chaudhuri et al., 1957). Most communications
have dealt with fluorouracil, though the riboside fluorodeoxyuridine (FUDR) has
been advocated more recently by Ansfield, Schroeder and Curreri 1962.
The purpose ofthis communication is to report on the treatment of 52 patients
with fluorinated pyrimidines (fluorouracil, fluorodeoxyuridine) in an effort to
compare results obtained with those two drugs, with emphasis on the real benefit
that can be obtained for some patients. Over 90% of the patients treated are
now dead, so that it is possible to assess the overall effect of these agents on the
life history of the patient with advanced carcinoma.J. J. FENNELLY AND M. X. FITZGERALD
MIATERIALS AND METHODS
Fifty-two patients with advanced malignancy, who had symptoms requiring
treatment, and who had had surgical forms of treatment previously were given
adequate courses of either 5-fluorouracil or FUDR as follows: colon 19, stomach 8,
pancreas 5, breast 9, ovary 6, lung 2, common bile duct 3. Patients who had
reached a terminal state were not included for treatment, nor were they included
if there was evidence of bone marrow depression. Only 1 patient over 70 years
was treated, since it is generally agreed that this age group tolerates this treatment
very poorly. 5-Fluorouracil was given by straight intravenous injection using
the modified load dosage recommended by Ellison (1962) as follows: 15 mg./kg./
weight straight intravenously daily for 3 days then 7-1 mg./kg./day intravenously
every second day to toxicity, which usually resulted in 3 to 7 days from the start
of treatment. Two weeks after clearing of toxicity maintenance therapy at
15 mg./kg. once weekly was adopted. No patient was given more than 1 g.
of fluorouracil in any one injection.
Fluorodeoxyuridine (FUDR) was given by continuous intravenous infusion in
dosage of 1 mg./kg./weight, each day's dosage running in over 24 hours to achieve
maximal effect (Sullivan and Miller, 1965). This treatment was continued to
first signs of toxicity which was usually 2 to 8 days from the start of treatment.
If the patient appeared to be responding, and there was no pressing contra-
indication on a medical or a social basis, a second loading dose was given 4 weeks
later as for the first course. From 2 weeks following complete clearance oftoxicity
maintenance drug effect was achieved by administration of fluorouracil by rapid
intravenous route 15 mg./kg./weight once weekly. In 3 patients with locally
recurrent colon neoplasms, FUDR was given by intra-aortic infusion using a
Fenwal pressure pump.
Toxicity
Haemoglobin, white cell and platelet counts were checked daily during time
of loading dose, and before each weekly maintenance injection. The absolute
indications of toxicity leading to cessation of the drug were as follows:
(a) Appearance of oral ulcers-these were sought actively as the patient was
not always aware of their presence. Many complained of dryness of the mouth
for 24 hours before ulceration appeared.
(b) Diarrhoea, which could not be related to purgatives.
(c) A reduction ofwhite cell count below 4000 c. mm. or platelets below 100,000
c. mm. Relative indication-a sharp drop in white cell count towards a leucopenic
level.
Responses
Objective responses were accepted where there was a measurable reduction
in disease, associated with improvement in patient's well being lasting over 1
month. Improvement in liver function tests was not accepted alone as evidence
of objective response. Subjective responses were accepted where clearance or
definite improvement in symptoms occurred on treatment. A category of effect
which must be more meaningful from a purely clinical point ofview is an improve-
ment of such a degree in a patient admitted requirinig treatment, that he or she
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can return home to carry on their normal routines. Such a phenomenon is not
inherent in the objective/subjective rating though it may be a result of such
response. As will be seen this occurred in all too few cases.
RESULTS
The number ofpatients and their response rate is shown in Table I and details
of individual responses are illustrated in Table II.
TABLE I.-Response ofPatients to 5-Fluorouracil and FUDR Treatment
Fluorouracil FUDR
Obj. Subj. Obj. Subj.
No. resp. resp. No. resp. resp.
Colon . 10 2 2 . 9 5* 1
Stomach 2 0 0 . 5 0 2
Pancreas . 3 0 1 . 2 0 1
C.B.D. . 2 0 0 2 0 0
Lung. - . 2 0 1
Breast . 3 1 0 . 7 2 0
Ovary 1 6 1 1
21 3 3 34 8 6
One patient each with mammary, ovarian and bile duct carcinoma was treated with both
fluorouracil and fluorodeoxyuridine.
* 2 patients received FUDR by intra-arterial infusion.
Colon carcinoma (19)
Nineteen patients received a full course of treatment. Ten received a total
of 13 courses offluorouracil, and 9 patients received 13 full courses of fluorodeoxy-
uridine. Two of 10 showed an objective response to fluorouracil, both getting
such marked relief of pain that they were able to return home.
Patient 1 (Table II), a 41 year old housewife obtained marked relief of
pain, associated with marked shrinkage of abdominal masses (which had
been provedhistologically to beneoplastic). The response lasted for 3 months
but then complete ureteric obstruction developed secondary to infiltration.
It was unfortunate for the patient that a ureterostomy carried out then
prolonged her life for 9 months more, sinice, being resistant to fluorouracil,
she continued to require treatment for extremely severe pain.
Patient 2, a 50 year old housewife with eqigastric pain and fever d1Ae to
hepatic metastases, and constipation, showed clearing of all complaints on
treatment with fluorouracil in subtoxic dosage.
In both patients the responses lasted only for 3 months, though they lived for
9 and 7 months respectively afterwards with persistent increasing symptoms.
Two other patients showed minor symptomatic improvement. Case No. 3 has
already been described (Fennelly 1967).
Of the 9 patients treated with FUDR (6 treated systemically and 3 intra-
arterially), 5 showed objective and subjective benefit, while one other had definite
relief of pain. Three of the total group treated systemically (patients 3, 4 and 5)
improved from a stage of incapacitation with pain and other symptoms so they
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TABLE II.-Details ofType ofResponme Achieved in Those Benefitingfrom Treatment
with Fluorinated Pyrimidines
Age/ Presenting
Patient Dx sex problem
1. M. M. Colon 41 F. Painful
abdom. mass
2. McL. ,, 50 F. Epigastric pain
and fever
3. B.I.
4. J.W.
5. M.C.
6. C.C.
,,9 55 M. Painand fever
,9 63 M. Pain and
constipation
,,1 64 M. Pain/bowel
obstruction
58 M. Pain/constipation
7. J.R. 44 M. Painful
abdom. masses
8. O.D. Pancreas 55 F. Epigastric pain
9. N.K. ,, 42 F. Epigastric pain I
10. P.E. Breast 50 F. Ulcerated chest
lesion
11. E.F. ,, 60 F. Painchest
recurrence
12. M.B. ,, 40 F. Recurrent chest
wall lesions
13. M.H. Lung 54 F. Painful hepatic
metastases
Drug Result
Fluorouracil Pain clear;
masses 70% reduced
,19, Pain and fever clear
FUDR Painand fever clear
,, Pain cleared
,13, Clearing ofbowel
obstruction and pain
,,(I.A.) Clearing ofsymptoms
mass reduced 400
,,(I.A.) Pain + mass
reduced 30%
Pain abated
Fluorouracil Pain clear
Partial healing of
chest wall lesion
FUDR Painful masses
reduced in size 200/
FUDR Masses reduced
40% in size
FUDR Reliefofpain only
Duration of Survival fron-
response chemotherap3
(months) (months)
3 12
4 9
6
5
11
12
7 8+
4
2
6
4
7+
8+
2 3
2 5
3
4
I. A. = intra-arterially.
were able to return home for periods of 7, 5 and 7 months respectively. The
last of these (Fig. 1) had subacute bowel obstruction at the time of admission,
and this cleared completely following 2 courses ofFUDR treatment which resulted
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FIG. 1.--Response of patient with colon carcinoma to FUDR followed by 5-fluorouracil.
WBC count 0 and platelet count C.
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also in a 40%. reduction in the size of a suprapubic recurrent mass. The response
in the patients treated intra-arterially (No. 6 and 7) consisted of shrinkage of
recurrent abdominal masses; however, once infusion was stopped there was a
rapid recrudescence of lesions and treatment was considered to have been oflittle
real benefit to the patients concerned.
Pancreas
Of the 3 patients treated with fluorouracil, one (patient 9) had marked relief
of very severe epigastric which lasted for 4 months, but relief was obtained only
at the expense ofdosage kept to a toxic level, i.e. it was only when diarrhoea was
being produced by the drug that real relief of pain was obtained; however, the
patient was glad to tolerate this while she experienced relief of pain. One of 2
patients treated with FUDR (patient 8) also obtained good relief of pain though
no objective criterion of response was obtainable. Both returned home to live
a normal life for 4 to 6 months respectively. One of the remaining 3 obtained
minor relief ofpain while the remaining 2 cases obtained no benefit.
Stomach
Of 7 patients treated, none showed a satisfactory response. It is inherent in
this condition that many of the patients at the time of presentation, because of
anorexia have lost much weight, and therefore are very unsuitable candidates
for any cytotoxic treatment. One patient treated with fluorouracil showed a
transient drop in serum bilirubin from 24 to 9-2 mg.% which was not accompanied
by any subjective clinical improvement. Two of the 5 patients treated with
FUDR noted mild transient relief of pain, but did not improve well enough to
leave hospital.
Lung
One ofthe 2 patients with hepatic metastases from lung carcinoma (patient 13)
noted relief of pain sufficient to enable her to return home for some months, but
there was no change in the size ofthe liver secondaries, or in persistently abnormal
liver function studies.
Common bile duct
No improvement resulted in treatment of 3 patients who presented with
complete biliary obstruction. Therapy did not affect or delay the rise in serum
bilirubin or alkaline phosphatase. No patient presenting with obstructive jaun-
dice as part of other malignant conditions obtained any real benefit.
Breast
Of 9 patients treated, 1 responded to fluorouracil, while 2 responded to FUDR.
Patient 10, P.E., who had failed to improve following adrenalectomy, showed
definite improvement in ulcerative chest wall recurrences, but, at the height of
toxicity she developed hyponatraemia with hypotension, probably due to faulty
absorption of orally administered replacement corticosteroids, since the serum
sodium and blood pressure returned to pretreatment levels following parenteral
administration ofhydrocortisone. Patients 11 and 12 showed reduction in painful
chest wall recurrences for 2 and 3 months respectively, but in terms of the overall
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survival of these patients this was a small contribution. It is important to
point out that all patients in this group had had full hormonal treatment followed
by alkylating agents, so they were in a quite advanced state of their disease,
whentreated withfluorinated pyrimidines.
Ovary
One patient with ovarian carcinoma who had developed low grade bowel
obstruction showed marked improvement in bowel function while another patient
developed partial clearing of a complete bowel obstruction. In neither case was
there any measurable objective evidence of improvement. A further patient
showed marked reduction in the size of palpable secondaries, but toxicity was of
such a degree that no benefit accrued to the patient who died 4 weeks following
treatment. While the blood count and bowel function had returned to normal,
it is felt that therapy did contribute to the patient's demise.
TABLE III.-Toxicity Produced by Treatment With 5-Fluorouracil and FUDR
Fluorouracil FUDR Total
Oralulcers . . 8/20 (40%) . 9/34 (26%) . 17 (31%)
Diarrhoea . . . 9/20 (45%) . 18/34 (53%) . 27/57 (50%)
Leucopenia
< 4000 . . . 9/20 (45%) . 25/34 (74%) . 34/57 (63%)
< 3000 . . . 2/20 (10%) . 11/34 (33%) . 13/57 (22%)
< 2000 . . . 2/20 (10%) . 2/34 (6%) . 4/57 (7%)
Thrombocytopenia
100,000 . . . 1 (5%) . 3/34 (9%) . 4/57 (7%)
Toxicity (Table III)
Since the programme adopted here was designed to give full dosage initially,
most patients showed some signs of toxicity during the time of loading dosage.
This was uncommon in patients on maintenance dosage, occurring only in 4
cases (8%). Fig. 2aand 2b give an outline oftheeffect ofFUDRand5-fluorouracil
respectively on the white cell and platelet counts at the stage ofmaximum marrow
depression and 1 week afterwards. In no case described here was thrombo-
cytopenia a prime reason for ending of treatment. Sixty-six per cent of patients
showed a reduction of white cell count below 4000 c. mm. while 4 showed a drop
below 2000 c. mm., but in no case did the count go below 1000 c. mm. In almost
all cases the white cell count had returned to pretreatment levels within 1 week of
cessation of drug therapy, but this return was slower in the case of fluorouracil.
Leucopenia was more frequent in those patients on FUDR (70% compared to
40%). Thrombocytopenia produced no clinical problem.
Oral ulceration developed in 31% of cases being more frequent in those treated
with fluorouracil. This was of little real discomfort to most subjects, though one
patient did develop marked pharyngitis associated with this ulceration. Diarr-
hoea developed in 50% of cases, a similar frequency in both groups studied. This
was usually controlled with Lomotiltablets (diphenoxylate andatropine) combined
with kaopectate. In a few cases it was necessary to supplement fluid intake by
intravenous infusion.
Alopeciawas a clinicalproblem onlyin 2 patients, who had developedprolonged
granulocytopenia after fluorouracil treatment, though other patients noted increas-
ing " falling out " of hair without cosmetic defects.
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Most patients complained of some degree of nausea. In those who were
confined to bed during treatment this posed little difficulty, but in the others
continuing on once weekly injections on an outpatient basis, nausea with vomiting
appeared to be much more distressing, so much so that one patient had to stop
treatment.
Sutrvival
What ofthe effect oftherapy on survival? Perusal ofFig. 3 suggests thatthose
patients responding to treatment survive for longer periods, though after 6 months
the mortality curve of responders resembles the rapid initial rate in patients
failing to respond to therapy. It is important to stress that some who responded
lived for periods up to 1 year, though they had benefited from the fluorinated
pyrimidines for periods much shorter than that. For this reason survival should
not be considered unless it is stressed in terms of quality of survival. The mean
length of response in those achieving benefit was 3 months, while the mean
survival rate from start oftherapy was 8 months.
DISCUSSION
In this group of 52 patients treated adequately with fluorinated pyrimidines,
39 (75%) achieved little or no benefit from treatment. Reports of large series
to date devoted mostly to fluorouracil indicate a variable response rate: Kennedy
and Theologides (1961) 21% of 118, with best response in mammary and gastric
carcinoma; Brennan et al. (1964) 16-8% of 594 cases, best results in colon, breast
and gastric carcinoma; Moertel and Reitemeier (1962) 19% of 112 with best
results in colon, stomach and pancreatic carcinoma; Sullivan and Miller (1965)
40% of56 cases with best results in colon, rectum, breast and stomach. It appears
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FIG. 3. Effect of response to treatment with fluorinated pyrimidines on survival curve of
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optimum effects are obtained in colo-rectal and breast carcinoma with variable
responses in pancreatic and gastric carcinoma. The regression rate obtained
does not compare with those of hormonal therapy in breast carcinoma; alkylating
agents, vinblastine or procarbazine in Hodgkin's disease or alkylating agents in
ovarian carcinoma. However, in a condition with such a hopeless outlook as
inoperable gastrointestinal carcinoma, we are obliged to achieve what we can with
the drugs available, and of these the fluorinated pyrimidines are the only group
that will produce a worthwhile benefit in some cases though the number is small.
Many cytotoxic drugs fall into disrepute because of hapazard administration,
and failure to follow accurate dosage. This holds particularly in the case of the
fluorinated pyrimidines, where a systematic, almost mathematical approach to
treatment must be adopted if good results are to be obtained and dangerous
toxicity avoided. Because of this, their use must be confined to those with a
detailed knowledge of their benefits and side effects.
The best responses in this series were noted in patients with colon carcinoma.
Of 19 subjects treated, 7 (37%0) achieved an objective response of whom 5 were
able to leave hospital, although the interval ofresponse was brief-2 to 7 months.
In advanced symptomatic colon carcinoma where all other treatments are so
unavailing, even such a result must be considered significant. No patient with
gastric carcinoma achieved a worthwhile benefit which is in contrast to some of
the reports already reported. However, these communications gave no indication
as to the subsequent fate of the patients who did respond.
Two patients with pancreatic carcinoma had marked relief of pain on treat-
ment, but in neither was a measurable parameter of disease available. This is
understandable where we may be dealing to a large extent with retroperitoneal
disease. Since two-thirds of patients with colon carcinoma, 90% with gastric,
and 99% with pancreatic carcinoma die within 5 years, a large number ofpatients
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with gastrointestinal malignancy will present at some stage for palliative therapy,
and in these cases, drugs such as the fluorinated pyrimidines should be considered.
Partial regressions in chest lesions were noted in 3 patients with breast carcin-
oma though the duration was short 2, 2 and 3 months respectively. In a
condition with such a variable history, and which is so responsive in many cases
for much longer periods to other treatments, such a result is of much less signifi-
cance than a similar result in colon carcinoma.
The toxicity produced by the drug when given in optimal dosage makes it
essential that patients be under close supervision at the time of loading dosage.
Once this is achieved the patient can be treated as an outpatient on maintenance
therapy. In the dose of 5-fluorouracil used in early studies, i.e. 15 mg./kg. x 5
davs, the mortality from different series was in the region of 5%. Using present
dosage and watching closely for toxic effects, the mortality with modified loading
of 5-fluorouracil dosage (15 mg./kg. x 3 days) should be minimal. One patient
in this series was considered to have expired as a result of debilitation induced by
drug toxicity. There probably is little difference in response rate whether one
uses fluorouracil or FUDR for induction of response, but the marrow recovery
rate following FUDR is more rapid than following fluorouracil. It is impractical
to consider FUDR for maintenance since the cost of weekly straight injection at
dosage of 30 mg./kg. would be excessive, and for this reason fluorouracil 15 mg./kg.
once weekly by rapid injection is best since minimal toxicity occurs, and initial
benefit can be maintained.
A question often raised is as regards the benefit of continuous infusion versus
straight injection of FUDR. For the former the optimal dose is 1 mg./kg./day
whereas for the latter approach 30 times the dose, i.e. 30 mg./kg., is required.
Sullivan and Miller claim "enhanced biological activity in terms of dose-toxicity
relation for prolonged infusion", a fact apparently borne out by their 40%
regression rate noted in 1965. On the other hand, in a controlled study Moertel,
Reitemeier and Hahn (1967) noted 17-5% response for straight injection versus
6.20% for slow injection of FUDR. Perusal of the latter paper however, indicates
that those showing a better response developed a greater degree of toxicity in
terms of leucopenia (72% as compared to 28%) so that those responding were
receiving a dose that was closer to the maximum tolerated dose.
It has been suggested that patients who have had an adrenalectomy respond
poorly to fluorinated pyrimidines (Tipton and Regan, 1963). This may be a
reflection of poor absorption of oral administered steroids given for maintenance
treatment. One patient in this series developed severe adrenal insufficiency,
probably due to failure of absorption of oral administered corticosteroids through
the iatrogenically induced denudation of surface epithelium of the small bowel.
Administration of replacement hormones by injection rapidly overcame that
problem.
SUMMARY
The fluorinated pyrimidines, 5-fluorouracil and fluorodeoxyuridine, have a
place in the management of advanced symptomatic colon carcinoma, and a lesser
place in mammary and pancreatic carcinoma. The toxicity of this group of
drugs precludes their use except in the most experienced of hands. Best results
can be obtained by induction of response with fluorouracil or FUDR, followed by
by maintenance of the effect with 5-fluorouracil given once weekly.
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